No Two Surfactants Are Alike

The success of a surfactant starts with its profile

You can tell a lot about a surfactant from its profile. Volume requirements, dosing schedule, concentration of key ingredients: each of these features may affect your experience with a surfactant. Take a closer look at the profile of CUROSURF® (poractant alfa) Intratracheal Suspension and consider how your experience with CUROSURF may be different than with other exogenous surfactants.

Comparison of exogenous surfactants

Lung surfactant products are composed of complex mixtures of ingredients, and clinical efficacy in vivo cannot be attributed to any one ingredient alone.

Lower volume and a higher phospholipid concentration set CUROSURF® (poractant alfa) apart from other exogenous surfactants.1

CUROSURF® (poractant alfa) Intratracheal Suspension*1,2 Surfaxin® (lucinactant) Intratracheal Suspension*3 Survanta® (beractant) Intratracheal Suspension2,4 Infasurf® (calfactant) Intratracheal Suspension2,5
Dosing
1st dose (mL/kg) 2.5 5.8 4 3
2nd dose (mL/kg) 1.25 5.8 4 3
Schedule Q12 hours Q6 hours Q6 hours Q12 hours
Single bolus delivery option Yes No No No
Composition
Source Porcine Synthetic Bovine Bovine
Phospholipid concentration
(mg/mL)
76 30 25 35
Dipalmitoylphosphatidyl-
choline (mg/mL)
30 22.5 11.0–15.5 16
SP-B (mg/mL) 0.45 Not Specified Not Specified 0.26
SP-C (μg protein/μmol • L-1
phospholipid)
5.0–11.6 Not Specified 1.0–20.0 8.1
Additives No No Yes No
Manufacturing
Organic solvent extraction Yes No Yes No
Liquid-gel chromatography‡ Yes No No No

*While both CUROSURF and Surfaxin are approved for neonatal RDS, CUROSURF is approved for treatment and Surfaxin is approved for prophylaxis. See labeled indications.
Volume of surfactant is measured in milliliters per kilogram of body weight at birth.
Neutral lipids such as triacylglycerol, cholesterol, and cholesteryl esters are filtered out of CUROSURF via liquid-gel chromatography. CUROSURF contains a higher proportion of polar lipids as a result of chromatography. In contrast, Survanta and Infasurf retain their neutral lipids and have relatively lower polar lipids.5-7

While clinical studies have demonstrated that SP-B, SP-C, and phospholipids are essential elements, they have not established the quantity required for optimal surfactant efficacy.

  • CUROSURF® (poractant alfa) is the only exogenous surfactant to undergo a liquid-gel chromatography purification step during manufacturing2,6
  • Liquid-gel chromatography allows CUROSURF to maintain a much higher concentration of polar lipids vs other exogenous surfactants1,4-6

Lower volume and a higher phospholipid concentration set CUROSURF® (poractant alfa) apart from other exogenous surfactants.1

For CUROSURF® (poractant alfa), the 200 mg/kg initial dose makes a difference8

 

Click below to learn more about the unique experience CUROSURF can offer in treating your infants with Respiratory Distress Syndrome (RDS).

Dosing: CUROSURF delivers more surfactant with less volume vs other exogenous surfactants.1,3-5

Clinical studies have not established that lower volume or fewer doses result in superior efficacy or safety based on clinically relevant end points.

Composition: An initial dose of CUROSURF delivers more than twice the phospholipid concentration (mg/mL) of other exogenous surfactants, and 44% more surfactant protein B (SP-B) than Infasurf.1,3-5

While clinical studies have demonstrated that SP-B, SP-C, and phospholipids are essential elements, they have not established the quantity required for optimal surfactant efficacy.

Manufacturing: CUROSURF delivers the highest level of surfactant in the lowest volume because of the extra purification steps taken during processing. CUROSURF is the only natural surfactant to undergo liquid-gel chromatography, an essential step for removing neutral lipids and other impurities in the suspension.1-6